<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="105" ids="17234">Glucose</z:chebi> and fatty acids comprise the primary substrates for myocardial energy metabolism </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:mpath ids='MPATH_458'>normal</z:mpath> myocardium switches toward <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism in the setting of stress; the inability to affect such a switch is a fundamental mechanism behind "diabetic" or "insulin-resistant" <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of this mechanistic study was to evaluate the effects of treatment with the dipeptidyl peptidase (DPP) 4 inhibitor <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> on myocardial <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake in patients with nonischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: Twelve nondiabetic subjects with nonischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> underwent metabolic testing and assessment of myocardial <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake by (18)F-fluorodeoxyglucose <z:chebi fb="4" ids="30225">positron</z:chebi>-emission tomographic/computerized tomographic imaging at baseline and after 4 weeks of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> therapy </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="40237">Sitagliptin</z:chebi> therapy resulted in a significant increase in myocardial <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake (19% increase; PÂ = .04) </plain></SENT>
<SENT sid="5" pm="."><plain>Although most patients had at least a slight increase in <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake, there was an overall bimodal response, with 6 patients ("responders") demonstrating large increases (&gt;20%) in <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake and 6 patients ("nonresponders") demonstrating &lt;5% increases or slight decreases </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="17855">Triglyceride</z:chebi>-<z:chebi fb="6" ids="39025">high-density lipoprotein</z:chebi> ratios significantly dropped in the 6 responders compared with the 6 nonresponders (P &lt; .02) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Therapy with the DPP-4 inhibitor <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> results in increased myocardial <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake in nondiabetic patients with nonischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
</text></document>